In January 2024, the first publication from the Polepi project was released.“Nanoparticle-Encapsulated Epirubicin Efficacy in the Inhibition of Growth of Orthotopic Ovarian Patient-Derived Xenograft in Immunocompromised Mice Int. J. Mol. Sci. 2024, 25(1), 645;”describing the development and study of the anti-tumor activity of Polepi in a selected PDX model of ovarian cancer. The paper was published by the Multidisciplinary Digital Publishing Institute (MDPI) in the International Journal of Molecular Sciences (IP 5.6).
Ovarian cancer, due to its anatomical location, shows symptoms when it is already at an advanced stage and is therefore difficult to treat. A well-known drug is epirubicin hydrochloride, which effectively kills cancer cells, but increasing the dose used is limited by its severe toxicity. Through the use of Polepi, we expected to deliver higher and thus clinically more effective doses directly to tumors, where epirubicin would be released and retained longer in the tumor. The antitumor activity of Polepi compared to epirubicin hydrochloride was first tested ex vivo on a series of tumor xenografts from ovarian cancer (PDX) patients. The most promising PDX was implanted orthotopically into immunocompromised mice, and tumor growth was monitored by magnetic resonance imaging (MRI). Although we were able to inhibit the growth of patient-derived ovarian cancer in a mouse model by 70% compared to 40% with epirubicin hydrochloride and reduce the time to tumor doubling by 2.5-fold within 5 days after a single intravenous administration, we could not eliminate serious side effects, and the study was terminated prematurely for humanitarian reasons.